Stage-specific expression of breast cancer-specific gene γ-synuclein

Kejin Wu, Ziyi Weng, Qinghua Tao, Gufa Lin, Xiangru Wu, Huiqin Qian, Yichu Zhang, Xiaoyan Ding, Yangfu Jiang, Yuenian Eric Shi

Research output: Contribution to journalArticlepeer-review

68 Scopus citations


γ-Synuclein (SNCG), also referred as breast cancer-specific gene 1, is the third member of a neuronal protein family synuclein. SNCG is highly expressed in human-infiltrating breast carcinomas but not expressed in normal or benign breast tissues. To evaluate the clinical relevance of SNCG expression in breast cancer progression and its correlation with clinical parameters, we analyzed SNCG expression in 79 clinical breast specimens from primary breast cancer, hyperplasia, and fibroadenoma patients by reverse transcription-PCR. The status of estrogen receptor, progesterone receptor, proliferating cell nuclear antigen, and C-erBb2 was also analyzed by immunohistochemistry. Overall SNCG mRNA expression was detectable in 38.8% of breast cancers. However, 79% of stage III/IV breast cancers were positive for SNCG expression, whereas only 15% of stage I/II breast cancers were positive for SNCG expression. In contrast, the expression of SNCG was undetectable in all benign breast lesions. The expression of SNCG was strongly correlated to the stage of breast cancer (P = 0.000). This study suggests that the expression of SNCG is stage specific for breast cancer. SNCG is expected to be a useful marker for breast cancer progression and a potential target for breast cancer treatment.

Original languageEnglish (US)
Pages (from-to)920-925
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Issue number9
StatePublished - Sep 1 2003


Dive into the research topics of 'Stage-specific expression of breast cancer-specific gene γ-synuclein'. Together they form a unique fingerprint.

Cite this